Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,356.25
(
-1.87%
)
US TECH 100
22,527.20
(
-1.85%
)
Dow Jones
45,071.59
(
-1.93%
)
Brent Oil
106.77
(
6.05%
)
Bitcoin
65,856.54
(
-4.27%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 216884

Wednesday, 02/07/2018 4:28:13 PM

Wednesday, February 07, 2018 4:28:13 PM

Post# of 257295
ENTA FY1Q18 results:

http://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-financial-results-its-fiscal-12

Revenue was $38.1M, of which $23.1M came from royalties and $15.0M from a milestone payment for Mavyret approval in Japan. GAAP EPS was $0.59.

Cash at 12/31/17 was $297.5M.

Gross operating expenses were $23.7M—well below the FY2018 quarterly guidance range of $30.5-34.5M.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today